Clinical outcomes in patients with node-negative breast cancer treated based on the recurrence score results: evidence from a large prospectively designed registrySalomon M. Stemmer, Nicky Liebermann, Christer Svedman et al.|npj Breast Cancer|2017Cited by 70
Ten-year clinical outcomes in N0 ER+ breast cancer patients with Recurrence Score-guided therapySalomon M. Stemmer, David Geffen, Mariana Steiner et al.|npj Breast Cancer|2019Cited by 30
Abstract P5-08-02: Real-life analysis evaluating 1594 N0/Nmic breast cancer patients for whom treatment decisions incorporated the 21-gene recurrence score result: 5-year KM estimate for breast cancer specific survival with recurrence score results ≤30 is >98%Salomon M. Stemmer, Nicky Liebermann, M. Steiner et al.|Cancer Research|2016Cited by 23
Ten-year clinical outcomes in >1000 node-negative (N0) Estrogen Receptor (ER)+ breast cancer (BC) patients (Pts) where treatment decisions incorporated the Recurrence Score Results: a registry analysis using TAILORx categorizationSalomon M. Stemmer, S. Shak, Michelle Leviov et al.|The Breast|2019Cited by 2
Treatments/clinical outcomes in ER+ HER2-negative breast cancer (BC) where treatment decisions were recurrence score (RS)-guided: Analysis by histologic subtype.Salomon M. Stemmer, Nicky Liebermann, Mariana Steiner et al.|Journal of Clinical Oncology|2017Cited by 0